UNSPSC 51286705: Ormetoprim

This classification denotes a dihydrofolate reductase inhibitor with the molecular formula C14H18N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M3EFS94984, chemically known as 2,4-pyrimidinediamine, 5-((4,5-dimethoxy-2-methylphenyl)methyl)- but more generally known as ormetoprim, which bears US NIH Compound Identifier 23418. European Medicines Agency schedules Ormetoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09463MIG.

The term ORMETOPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, No. 10 1969, List 9). ORMETOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1CC(CC2C(NC(NC2)N)N)C(CC1OC)C)C.

UNSPSC 51286705 Ormetoprim, a Commodity code, does not align with the recent state and local opportunities tagged to it. The opportunities instead span naloxone and drug deactivation systems (emergency response), direct-to-manufacturer prescription programs (state health policy), medical and first aid supplies for fire rescue (emergency medical consumables), and generic pharmaceutical and OTC product supply through cooperative purchasing agreements. The code's nominal scope — ormetoprim, a specific antimicrobial active pharmaceutical ingredient — does not match the work actually being solicited. State and local governments purchasing under this code tag show little relevant recent activity tied to ormetoprim itself; the mismatch suggests either data-entry error in opportunity classification or the code's practical inactivity in recent state and local procurement.

Geographic distribution across the recent records spans Florida (Seminole County), Texas (HHS Commission), and Minnesota cooperative membership with Oregon participation. Issuing bodies include county health departments, state health agencies, city fire departments, and multistate cooperative purchasing vehicles. The Texas HHS RFI (posted April 3, 2026) and the Minnesota MMCAP RFP (due March 26, 2026) represent forward-looking pharmaceutical procurement mechanisms at state scale, while the Seminole County IFB (due July 26, 2023, though posted June 30, 2026) and Tampa Fire Department IFB (due March 13, 2026) reflect operational procurement for emergency services and medical consumables. No solicitations directly specify ormetoprim acquisition or pharmaceutical intermediate supply relevant to the code's nominal scope.